total knock out

Photos: Houston innovation leaders weigh in on cybersecurity, tech, and more at inaugural event

The Digital Fight Club made its Houston debut on November 20 at White Oak Music Hall. Emily Jaschke/InnovationMap

What do you get when you cross the information of an innovation panel with the ferocity of a boxing match? A verbal sprawling among innovation leaders that can only be known as the Digital Fight Club.

Houston's DFC came about with the help of Accenture, which had been a partner at the Dallas events, and InnovationMap, who teamed up as presenting sponsors for the event. DFC's founder, Michael Pratt, came up with the idea for Digital Fight Club as a way to liven up technology-focused events and networking opportunities.

The setup of the event is five fights, 10 fighters, and five judges. Each fighter has just a couple minutes to take their stand before the event moves on.

"This is Digital Fight Club," says Pratt, CEO of the company. "You get subject matter experts, and serious founders and CEOs on the stage and make them make their case. You learn something, it's a lot of fun, and it's a lot better than a panel."

The hour of fighting is coupled with a VIP event ahead of the showdown and an after party where further networking can continue on. At Houston's VIP event, InnovationMap got to check in with partners, fighters, and referees about how they thought the event was going to pan out. Check out the VIP event video here.

The panel of referees included GabriellaRowe, CEO of Station Houston; DeniseHamilton, CEO of Watch Her Work; TimKopra, partner at Blue Bear Capital; LanceBlack, Director at TMCx; and BarbaraBurger, president of Chevron Technology Ventures.

The refs asked two questions per fight, and were able to vote on the winners of each round — as was the audience through an interactive web-based application. The break down of the fights, topics, and winners are as follows:

Fight #1: Future Workforce of Robotics/AI. Matt Hager, CEO of Poetic Systems, vs Pablo Marin, senior AI Leader, Microsoft. Hager took the win with 77 percent of the vote.
Fight #2: Whose responsibility is cybersecurity. Ted Gutierrez, CEO of SecurityGate vs Tara Khanna, managing director and Security Lead at Accenture. Khanna won this round, snagging 66 percent of the votes.
Fight #3: Oil & Gas Industry and the Environment. Michael Szafron - commercial adviser for Cemvita Factory, vs Steven Taylor, co-founder of AR for Everyone. Szafron received 76 percent of the voites, securing the win.
Fight #4: Digital in our personal lives. Grace Rodriguez, CEO of ImpactHub, vs Javier Fadul, chief innovation officer at HTX Labs. Rodriguez won with the largest margin of the night — 85 percent.
Fight #5: Future of Primary Care Geetinder Goyal, CEO of First Primary Care, vs Nick Desai, chief medical information officer at Houston Methodist. Goyal received 72 percent of the votes to take home the win.

The fights were heated, and some of the fighters had knockout quotes, from Hager's "AI is mostly bullshit" to Khanna's "Compliance doesn't mean you're secure." For more of the knockout quotes, click here.

Game faces

Emily Jaschke/InnovationMap

Each of the matches were quite heated, even when some of the participants more or less agreed on the topic. Part of the deal with being a fighter is creating an engaging conversation.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted